Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Cardiovascular · Investigational

Angiotensin (1-7)

No lawful US pathway

Tell me if this changesRead the free 2026 Peptide Safety Checklist →
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

Angiotensin (1-7) is a seven-amino acid peptide of the renin-angiotensin system, generated from angiotensin II by ACE2 or from angiotensin I by endopeptidases, and acting mainly at the Mas receptor (PMID 29351514). Through this receptor it opposes many actions of angiotensin II, with vasodilator, antiproliferative, antifibrotic, and anti-inflammatory effects described in experimental systems (PMID 29351514).

This counter-regulatory arm is a therapeutic target in hypertension, heart failure, and renal disease.

02 · Research summary & key findings

In rodents, angiotensin (1-7) prevented angiotensin II-induced cardiac remodeling (PMID 17098828) and reduced cardiac fibrosis in a DOCA-salt hypertension model (PMID 16415071). In humans, intra-arterial angiotensin (1-7) caused dose-dependent forearm vasodilation in both normotensive and hypertensive subjects (PMID 11463766). Clinical development has been limited by the peptide's short half-life: a phase 1 oncology study defined a tolerable dose with dose-limiting neurological toxicity at higher doses (PMID 19920106), and a randomized trial of synthetic angiotensin (1-7) (TXA-127) in hospitalized COVID-19 patients was stopped early for futility (PMID 37039791).

03 · Regulatory status

Angiotensin (1-7) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

No lawful pathway today

Angiotensin (1-7) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.

See the 4 FDA-approved compounds in Cardiovascular

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

04 · Administration routes

  • Subcutaneous injection
  • Intravenous
  • Oral

References

  1. [1]Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension Hypertension, 2001. PMID 11463766
  2. [2]Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension Am J Physiol Heart Circ Physiol, 2006. PMID 16415071
  3. [3]Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7) Am J Physiol Heart Circ Physiol, 2007. PMID 17098828
  4. [4]Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone Clin Cancer Res, 2009. PMID 19920106
  5. [5]The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7) Physiol Rev, 2018. PMID 29351514
  6. [6]Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials JAMA, 2023. PMID 37039791

Primary literature

Related peptides in Cardiovascular

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.